health
Satralizumab Trials Show Thyroid Eye Disease Improvements
Subcutaneous satralizumab improves proptosis, clinical activity, and diplopia in patients with active or inactive thyroid eye disease.
Satralizumab, an anti–interleukin-6 receptor antibody, has demonstrated clinically meaningful improvements in proptosis, disease activity, and diplopia among patients with thyroid eye disease (TED), according to research published in Ophthalmology.
R... [2603 chars]
Read Full ArticleShare this story
Up next
Related Stories
Should naloxone kits be available in public places with defibrillators?
Sootoday
Four things you need to know about deprescribing | Folio
University Of Alberta
Blood test detects breast cancer more than a year before scans
The Brighter Side of News
.jpeg;w=960;h=640;mode=crop)
Parents urged to ask about RSV immunization for eligible infants
Barrie News
London doctors perform Canada's first ‘heart in a box’ transplant
London Free Press